New treatment for drug-resistant tuberculosis commences in Papua New Guinea
Evelyn Lavu Travel Scholarship
Burnet welcomes Dr Andrew Nash to its Board of Directors
Providing support to the people of Myanmar
Research Reports + Policy Briefs
IMPACT Magazine
Events
Research Articles
How Science Matters Podcast
Study at Burnet
"Quick, simple, and friendly": Understanding the acceptability and accessibility...
Antimicrobials for Neonates: Practitioner Decisions and Diagnostic Certainty.
Factors Associated with Timely First-Dose Pentavalent and Measles-Rubella Vaccin...
Agency in young people’s unsafe abortion trajectories in Papua New Guinea.
Vaccines
Diagnostics
Therapeutics
Antibody Platforms
Australia
Papua New Guinea
Myanmar
People of Burnet
Leadership
Burnet Partners
Board Members
Appeals
Monthly Giving
Trusts + Foundations
Corporate Supporters
Giving in Wills + Bequests
Supporter Stories
About Us
Careers
History
Annual + Financial Reports
Burnet Institute is developing platforms to enhance efficacy of antibodies, Fc-fusion proteins, and antibody-like biologics that have potential application in oncology, infectious disease and immunological conditions.
Find us at BIO 2024 this June.
A hexamerising technology that transforms the potency of monoclonal antibodies (mAb), Fc fusion prot...
